US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain (pictured, above) as its new chief executive (CEO), and as a member of the board of directors.
According to BioCentriq, Mr Husain was chosen for his extensive expertise in CDMO development and manufacturing services, with a deep understanding of the cell and gene therapy supply and value chains.
His experience spans the entire drug development and commercialization lifecycle, including more than 20 years of strategic management, leading companies through rapid growth, go-to-market innovation and industry disruption.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze